Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03949283 · ClinicalTrials.gov registry record · Phase 3
Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
A Phase 3 study of Recurrent Ovarian Carcinoma and Platinum-resistant Ovarian Cancer, sponsored by Cordgenics.
- Active
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 8
- Study locations
NCT03949283 is a Phase 3 study of Recurrent Ovarian Carcinoma and Platinum-resistant Ovarian Cancer that is active but no longer recruiting, run by Cordgenics. The registered enrollment target is 150 participants, above the 120-participant average among 39 other Recurrent Ovarian Carcinoma trials with a reported enrollment target (25% higher). The trial reports 8 study locations across 7 states.
The verdict
NCT03949283, a Phase 3 study of Recurrent Ovarian Carcinoma and Platinum-resistant Ovarian Cancer, is active but no longer recruiting, sponsored by Cordgenics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this clinical study is to confirm the utility of chemosensitivity (ChemoID) tumor testing on cancer stem cells as a predictor of clinical response in recurrent platinum resistant epithelial ovarian cancer (EOC), fallopian tube, or primary peritoneal cancer. Population studied will be female participants experiencing a recurrent platinum-resistant ovarian cancer (no mucinous, low grade serous, or pure sarcoma types), with ≤ 5 prior treatments, and a performance status 0-1.
Conditions Studied
Interventions
- DRUG Standard Chemotherapy
- DIAGNOSTIC_TEST ChemoID Assay
Study Locations (8)
West Virginia
- Charleston Area Medical Center (CAMC) - Charleston
- Edwards Comprehensive Cancer Center - Cabell Huntington Hospital - Huntington
California
- Kaiser Permanente - Los Angeles
Florida
- Miami Cancer Institute/Baptist Health South Florida - Miami
Louisiana
- LSU Health Sciences Center - New Orleans
Ohio
- University of Cincinnati Cancer Institute - Cincinnati
Oklahoma
- University of Oklahoma Health Sciences Center - Oklahoma City
Pennsylvania
- West Penn Hospital, Allegheny Health Network - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2019-07-26 |
| Est. Completion | 2024-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03949283
The ClinicalTrials.gov registry entry for NCT03949283 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 120-participant average among 39 other Recurrent Ovarian Carcinoma trials with a reported enrollment target (25% higher). The listed sponsor is Cordgenics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent Ovarian Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Standard Chemotherapy is the first listed.
NCT03949283 reports 8 study locations spanning 7 distinct geographic areas - top geographies include West Virginia, California, Florida.
Frequently Asked Questions
What is clinical trial NCT03949283 about?
NCT03949283 is a clinical study titled "Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer". The purpose of this clinical study is to confirm the utility of chemosensitivity (ChemoID) tumor testing on cancer stem cells as a predictor of clinical response in recurrent platinum resistant epithelial ovarian cancer (EOC), fallopian tube, or primary peritoneal cancer. Population studied will be...
What is the current status of trial NCT03949283?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2019-07-26. Estimated completion is 2024-12-30.
What conditions does trial NCT03949283 study?
This clinical trial studies the following conditions: Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer.
What interventions are being tested in trial NCT03949283?
The interventions under investigation include: Standard Chemotherapy (DRUG), ChemoID Assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03949283?
This trial is sponsored by Cordgenics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03949283 being conducted?
This trial has 8 study locations across California, Florida, Louisiana, Ohio, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Ovarian Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
RECRUITING · Phase 1
-
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
RECRUITING · Phase 1
-
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
RECRUITING · Phase 2
-
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
RECRUITING · Phase 2
-
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
RECRUITING
Explore more on PlainTrial
Recurrent Ovarian Carcinoma
All registered trials for this condition
Platinum-resistant Ovarian Cancer
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.